^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tevimbra (tislelizumab-jsgr)

    i
    Other names: BGB-A317, BGB A317, VDT482, BGBA317, VDT 482, VDT-482
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    17h
    Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    19h
    A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Apr 2026 --> Dec 2027
    Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    Signatera™
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    1d
    Solitary adrenal metastatic adenocarcinoma one year after radical gastrectomy for gastric cancer: a case report. (PubMed, Front Med (Lausanne))
    The patient completed six cycles of adjuvant chemotherapy with tegafur-gimeracil-oteracil (S-1) plus oxaliplatin, and routine follow-up examinations showed no evidence of recurrence...The patient was treated with SOX chemotherapy combined with the PD-1 inhibitor tislelizumab...This case highlights the importance of vigilance for rare metastatic sites, such as the adrenal gland, in patients with advanced gastric cancer even after standardized postoperative surveillance. Systemic chemotherapy combined with immunotherapy may represent an effective treatment strategy for selected patients with metastatic gastric cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9)
    |
    Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    4d
    Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer. (PubMed, Oncology (Williston Park))
    Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1-positive subgroups, suggesting biomarker-driven therapeutic selection. These findings underscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical insights for personalized treatment strategies.
    Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    4d
    IKF-ReWoLuTe: Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab (clinicaltrials.gov)
    P=N/A, N=240, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New trial • Checkpoint inhibition • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK positive • ALK mutation
    |
    Tevimbra (tislelizumab-jsgr)
    5d
    DTP-HER2: A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Kolupin (tunlametinib)
    6d
    Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors (clinicaltrials.gov)
    P2, N=189, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Herceptin (trastuzumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    6d
    Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. (clinicaltrials.gov)
    P2, N=36, Completed, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    6d
    SOLTI-2101: Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer (2023-508828-35-01)
    P2/3, N=316, Completed, Solti Group | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Ibrance (palbociclib) • Tevimbra (tislelizumab-jsgr) • Kisqali (ribociclib)
    6d
    LBL-007-CN-004: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (clinicaltrials.gov)
    P1/2, N=98, Completed, Nanjing Leads Biolabs Co.,Ltd | Recruiting --> Completed | N=490 --> 98 | Trial completion date: Jul 2026 --> Jan 2026 | Trial primary completion date: May 2026 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007)
    6d
    First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up. (PubMed, Esophagus)
    After 3 years, first-line tislelizumab plus chemotherapy demonstrated sustained efficacy and a tolerable safety profile in Japanese patients with unresectable locally advanced/metastatic ESCC, consistent with the global RATIONALE-306 population.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Tevimbra (tislelizumab-jsgr)
    7d
    Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=50, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)